BUND FINANCE

BUND FINANCE › Stocks › AMGN

Amgen Inc. (AMGN)

NASDAQ · Stock price, chart and technical analysis

US$443.89-14.04 (-3.07%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$457.93
OpenUS$451.78
Day rangeUS$441.63 – US$455.05
52-week rangeUS$312.39 – US$483.99
Market capUS$240.11B
Volume2.58M
50-day averageUS$427.10
200-day averageUS$382.18
Beta0.42
Last dividend per shareUS$9.94

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$26.0BUS$26.3BUS$28.2BUS$33.4BUS$36.7B
Net incomeUS$5.9BUS$6.6BUS$6.7BUS$4.1BUS$7.7B
EPS (diluted)10.2812.1112.497.5614.23
Gross margin75.2%75.7%70.2%61.5%70.8%
Operating margin29.4%36.3%28.0%21.7%29.1%
Net margin22.7%24.9%23.8%12.2%21.0%
Free cash flowUS$8.4BUS$8.8BUS$7.4BUS$10.4BUS$8.1B
Total debtUS$33.3BUS$38.9BUS$64.6BUS$60.1BUS$54.6B
CashUS$8.0BUS$7.6BUS$10.9BUS$12.0BUS$9.1B

Compound annual growth: revenue 9.1% · net income 7.0% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E25.8x24.7x27.1x
EV / EBITDA15.5x13.8x16.5x
Operating margin35.5%—3.6%
Net margin24.1%—-0.0%
Debt / equity5.69—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Amgen Inc.

SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
CEORobert A. Bradway
Employees31,500
IPO date1983-06-17

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infectio…

www.amgen.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice